Chinese researchers just released a study that wanted to find out if the well-known vitamin folic acid would help to prevent strokes. The China Stroke Primary Prevention Trial was conducted from 2008 to 2013 in 32 communities in China on 20,702 adults with high blood pressure.
All participants were given the drug Enalapril (an ACE inhibitor commonly used to treat high blood pressure), but some were also given a folic acid supplement to see if the combination would be more effective in reducing stroke than Enalapril alone.
For four and a half years, participants received a daily pill either containing both 10 mg Enalapril and 0.8 mg folic acid or just 10 mg Enalapril. Compared with the Enalapril-only group, the Enalapril–folic acid group had a significant risk reduction in incidences of stroke and other cardiovascular conditions, including those that ended in death.
Researchers concluded that among adults with hypertension in China who had never had a stroke or heart attack, using folic acid along with blood pressure medication may further reduce risks.
(Yong Huo, MD; Jianping Li, MD, PhD; Xianhui Qin, PhD et al. “Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China”, : Peking University First Hospital, Beijing, China1Department of Cardiology, Peking University First Hospital, Beijing, China
2National Clinical Research Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China
3Institute for Biomedicine, Anhui Medical University, Hefei, China
4Department of Neurology, Peking University First Hospital, Beijing, China
5Department of Population, Family, and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
6Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
7Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
8School of Health Administration, Anhui Medical University, Hefei, China
9Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China
10Department of Neurology, First People’s Hospital, Lianyungang, China
11Department of Neurology, First Affiliated Hospital of Anhui Medical University, Hefei, China
12Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
13Department of Pharmacy, Peking University First Hospital, Beijing, China
14Department of Cardiology, Peking University People’s Hospital, Beijing, China
15Department of Geriatric Cardiology, General Hospital of the People’s Liberation Army, Beijing, China
16Department of Cardiology, Second Affiliated Hospital, Nanchang University, Nanchang, China
17Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
18Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
19Department of Cardiology, Xiangya Hospital, Central South University, Changsha, China
20Department of Cardiology, First Hospital of Shanxi Medical University, Taiyuan, China
21Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
22Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
23State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
24Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China
25Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China
26Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an, China
27Division of Hypertension, Fu-wai Hospital, Beijing, China
28Beijing Hypertension League Institute, Beijing, China JAMA. 2015;313(13):1325-1335.)